EDITOR: Kerrin M. Green, MA, Assistant Managing Editor, JNCCN— Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.
CE AUTHORS: Deborah J. Moonan, RN, BSN, Manager, CE Supporter-Outreach, has disclosed the following relationships with commercial interests: AstraZeneca: Stockholder/Former Employee. Ann Gianola, MA, Manager, Medical Education Accreditation and Grant Development, has disclosed the following relationship with commercial interests: Actelion: Grant/Research Support. Dorothy A. Shead, MS, Director, Patient & Clinical Information Operations, has disclosed that she has no relevant financial relationships. Maria Ho, PhD, Oncology Scientist/Senior Medical Writer, has disclosed that she has no relevant financial relationships.
GaztanagaMCrookJ. Androgen deprivation therapy: minimizing exposure and mitigating side effects. J Natl Compr Canc Netw2012;10:1088–1095; quiz 1088 1096.
ShawGLWilsonPCuzickJ. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int2007;99:1056–1065.
AkakuraKBruchovskyNGoldenbergSL. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer1993;71:2782–2790.
KlotzLTorenP. Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?Curr Oncol2012;19:S13–21.
NiraulaSLeLWTannockIF. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol2013;31:2029–2036.
CrookJMO’CallaghanCJDuncanG. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med2012;367:895–903.
PiaggioGElbourneDRPocockSJ. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA2012;308:2594–2604.
LoblawDAVirgoKSNamR. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol2007;25:1596–1605.
Calais da SilvaFEBonoAVWhelanP. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol2009;55:1269–1277.
de LevalJBocaPYousefE. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer2002;1:163–171.
MillerKSteinerULingnauA. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract]. J Clin Oncol2007;25(Suppl 18):Abstract 5015.
MottetNVan DammeJLoulidiS. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. BJU Int2012;110:1262–1269.
SalonenAJTaariKAla-OpasM. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol2012;187:2074–2081.
SalonenAJTaariKAla-OpasM. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects. Eur Urol2013;63:111–120.
JanjanNLutzSTBedwinekJM. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med2009;12:417–426.
Pandit-TaskarNBatrakiMDivgiCR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med2004;45:1358–1365.
HenriksenGBreistolKBrulandOS. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res2002;62:3120–3125.
HenriksenGFisherDRRoeskeJC. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med2003;44:252–259.
FizaziKCarducciMSmithM. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet2011;377:813–822.
SaadFGleasonDMMurrayR. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst2004;96:879–882.
US Food and Drug Administration. Radium-223 dichloride label information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203971lbl.pdf. Accessed September 13 2013.